Laboratory investigations in hemostasis

Optimizing the clinical management and understanding the physiopathological mechanisms underlying thrombotic pathologies. Hemocompatibility testing of biomaterials & Nanotoxicology

Principal Investigator

Prof. Jean-Michel Dogné

UNamur, Department of pharmacy 

Member of the Namur Thrombosis & Hemostasis Center (NTHC)

Member of the Namur Nanosafety Center (NNC)

Member of the Namur Medicine & Drug Innovation Center (NAMEDIC)

Research portal UNamur  |  ORCID  |  ResearchGate  |  LinkedIn

Expertise and research interests

Jean-Michel Dogné obtained his Pharm. D. from the University of Liège in 1996 and continued his studies in the laboratory of medicinal chemistry at the same university, where he received his Ph.D. in pharmaceutical sciences in November 2000. He was appointed Professor at the University of Namur in 2005 where he is currently head of the Department of Pharmacy. His research interests include the development and monitoring of antiplatelet and anticoagulant agents, the hemocompatibility of biomaterials and nanotoxicology. 

Prof. Jean-Michel Dogné is leading research projects in the field of thrombosis and hemostasis. His research activities contribute to optimizing the clinical management of thrombotic pathologies and to understanding the physiopathological mechanisms underlying the disease. He has been studying drug-induced thrombosis in patients with malignancy and shed light on extracellular vesicle-mediated anti-cancer drug resistance.

Moreover, Jean-Michel Dogné has a strong expertise in hemocompatibility testing of biomaterials and safety evaluation of nanoparticles. He was involved in several large-scale European projects such as NANOGECO and NANOHEART.

More recently, in response to the coronavirus pandemic, he is participating in clinical laboratory investigations related to Covid-19.

He is member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA since 2012 and the Global Advisory Committee on Vaccine Safety (GASVS) of the WHO since 2020.

Group members

PhD students: Happy Djokoto, Marie Didembourg, Jonathan Evrard, Constant Gillot, Hélène Haguet, Natalie Lan Linh Tran and Laure Morimont

Research projects

Thrombosis and hemostasis

  • ONGOING The THROMBIMMUN project: Relationship between inflammation, immunity and thrombosis. Ongoing PhD thesis by Constant Gillot. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The HIC project: Evaluation of hormone-induced coagulopathy. Ongoing PhD theses by Laure Morimont and Marie Didembourg. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The BIOCOAG project: Biological assessment of the control of anticoagulation. Ongoing PhD thesis by Romain Siriez. Under co-supervision by Prof. Jean-Michel Dogné, UNamur, NARILIS (promoter), Dr. Julie Laloy, UNamur, NARILIS (co-promoter) and Prof. François Mullier, CHU UCL Namur, Hematology laboratory (co-promoter).
  • ONGOING The CAF project: A new tool for the assessment of the clot formation. Ongoing PhD thesis by Jonathan Evrard. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter) and Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter).
  • ONGOING The TiTKI project: Evaluation of the risk of thrombosis associated with the use of tyrosine kinase inhibitors. Ongoing PhD thesis by Hélène Haguet. Under co-supervision by Prof. Jonathan Douxfils, UNamur, NARILIS (promoter), Prof. Jean-Michel Dogné, UNamur, NARILIS (co-promoter) and Prof. François Mullier, CHU UCL Namur, Hematology laboratory (co-promoter).
  • ONGOING The MAS project: Measure And See the activity of direct oral anticoagulant in the clinical context. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Romain Siriez), Clinique Saint-Luc Bouge (Julien Favresse) and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).
  • ONGOING The AVRI project: Evaluation of the risk of radiotherapy-induced atherosclerosis. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Dr. Céline Bouvy) and ULiège (Prof. Cécile Oury, Nathalie Donis).

 Hemocompatibility of biomaterials - Nanotoxicology

  • ONGOING Nano4Life: Innovative multidrug nanomedicines for myocardial ischemia reperfusion injuries treatment. Ongoing PhD thesis by Natalie Lan Linh Tran. Joint PhD programme at UNamur (Prof. Jean-Michel Dogné) and Université Paris-Saclay (Prof. Patrick Couvreur).
SARS-CoV-2
  • ONGOING The COVILAB project: Clinical laboratory investigations related to COVID-19. Research collaboration between UNamur (Prof. Jonathan Douxfils, Prof. Jean-Michel Dogné, Hélène Haguet, Constant Gillot and Laure Morimont), QUALIblood (Prof. Jonathan Douxfils, Céline Bouvy, Laure Morimont and Sabrina Melchionda), Clinique Saint-Luc Bouge (Julien Favresse), Hôpitaux Iris Sud (Dr. Marie Tre-Hardy), and CHU UCL Namur (Prof. François Mullier and Dr. Michaël Hardy).

Selected publications

Siriez R, Alpan L, Elasaad K, Devel P, Laloy J, Dogné JM, Douxfils J. Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method. J Thromb Thrombolysis. 2020 Apr;49(3):395-403.

Evrard J, Morimont L, Didembourg M, Haguet H, Siriez R, Dogné JM, Douxfils J. Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETP-based APC resistance. Int J Lab Hematol. 2020 Dec 12.

Haguet H, Bouvy C, Delvigne AS, Modaffari E, Wannez A, Sonveaux P, Dogné JM, Douxfils J. The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Front Pharmacol. 2020 Jul 3;11:1007.

Devalet B, Wannez A, Bailly N, Alpan L, Gheldof D, Douxfils J, Bihin B, Chatelain B, Dogné JM, Chatelain C, Mullier F. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles. Medicine (Baltimore). 2019 Jul;98(27):e16164.

Sennesael AL, Larock AS, Devalet B, Mathieux V, Verschuren F, Muschart X, Dalleur O, Dogné JM, Spinewine A. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study. Br J Clin Pharmacol. 2018 Jul;84(7):1544-1556.

Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. Biomark Cancer. 2018 Jun 18;10:1179299X18781095.

Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging. Clin Appl Thromb Hemost. 2018 Jan;24(1):129-138.

Wannez A, Devalet B, Bouvy C, Laloy J, Bihin B, Chatelain B, Chatelain C, Dogné JM, Mullier F. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thromb Res. 2017 Jun 9;156:142-148.

Minet V, Baudar J, Bailly N, Douxfils J, Laloy J, Lessire S, Gourdin M, Devalet B, Chatelain B, Dogné JM, Mullier F. Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry. Thrombosis research 2014, 133:1074-1078.

Laloy J, Minet V, Alpan L, Mullier F, Beken S, Toussaint O, Lucas S, Dogné JM. Impact of Silver Nanoparticles on Haemolysis, Platelet Function and Coagulation. Nanobiomedicine (Rij). 2014 Jan 1;1:4.

Contact

jean-michel.dogne@unamur.be